Study of Bepirovirsen in Nucleos(t)Ide Analogue-treated Participants With Chronic Hepatitis B (B-Well 1)

NCT05630807 | Active Not Recruiting Phase 3 DMC FDA Drug

• 2 other identifiers: 2020092021-005139-22
• Study Type: interventional
• Target: 981
• Locations: 26 countries
• Sites: 177

Brief Summary

This study is intended to confirm the efficacy, safety, pharmacokinetic (PK) profile, and the durability of hepatitis B virus surface antigen (HBsAg) suppression observed with bepirovirsen for 24 weeks (with loading doses) as compared to the placebo arm. This study will have 4 stages: a) Double-blind treatment (bepirovirsen or placebo) for 24 weeks. b) Nucleos(t)ide analogue (NA) treatment for 24 weeks. c) NA cessation stage OR Continue NA for 24 weeks. d) Durability of response and follow up for further 24 weeks for participants who stopped NA treatment at Week 48. The arms will be stratified based on HBsAg level (HBsAg greater than or equal to \[≥\] 100 international unit per milliliter \[IU/mL\] to less than or equal \[≤\]1000 IU/mL or greater than \[\>\] 1000 IU/mL to ≤3000 IU/mL) at screening. The total duration of the study, including screening (up to 60 days), the double-blind treatment stage (24 weeks), the On NA only stage (24 weeks), and the NA cessation and durability stages (48 weeks) is up to approximately 104 weeks at maximum for each participant.

Conditions

Chronic Hepatitis B; Hepatitis B, Chronic

Keywords

Hepatitis; Chronic Hepatitis; Chronic Hepatitis B; Hepatitis B Virus; hepatitis B virus e-antigen; Bepirovirsen; Nucleos(t)ide analogue; Antisense Oligonucleotide; 202009; 219288

Outcome Measures

Primary Outcomes (1)

• Number of participants achieving functional cure (FC) with baseline HBsAg ≤3000 IU/mL

  The number of participants who achieved FC after discontinuation of all chronic HBV treatment (bepirovirsen/placebo and NA) in the absence of rescue medication will be reported. The FC for HBV is defined as Sustained suppression (24 weeks or longer) of HBV DNA \< Lower limit of quantification (LLOQ) off all HBV treatment and HBsAg not detected with or without HBsAb after a finite duration of therapy.

  Up to 72 weeks

Secondary Outcomes (3)

• Number of participants achieving FC with baseline HBsAg ≤1000 IU/mL

  Up to 72 weeks

• Number of participants achieving sustained suppression of HBV DNA (<LLOQ) with baseline HBsAg ≤3000 IU/mL

  Up to 72 weeks

• Number of participants achieving sustained suppression of HBV DNA (<LLOQ) with baseline HBsAg ≤1000 IU/mL

  Up to 72 weeks

Study Arms (2)

Bepirovirsen

EXPERIMENTAL

Drug: Bepirovirsen

Placebo

PLACEBO COMPARATOR

Other: Placebo

Interventions

Bepirovirsen DRUG

Bepirovirsen will be administered.

Bepirovirsen

Placebo OTHER

Matching placebo will be administered.

Placebo

Eligibility Criteria

• Age: 18 Years+
• Sex: all
• Healthy Volunteers: No
• Age Groups: Adult (18-64), Older Adult (65+)

You may qualify if:

• Participants who have documented chronic HBV infection ≥6 months prior to screening and currently receiving stable NA therapy defined as no changes to their NA regimen from at least 6 months prior to Screening and with no planned changes to the stable regimen over the duration of the study.
• Plasma or serum HBsAg concentration \>100 IU/mL, but no greater than ≤3000 IU/mL.
• Plasma or serum HBV DNA concentration must be adequately suppressed, defined as plasma or serum HBV DNA \<90 IU/mL.
• Alanine aminotransferase (ALT) ≤2 × upper limit of normal (ULN).
• Participants who are willing and able to cease their NA treatment in accordance with the protocol.

You may not qualify if:

• \- Clinically significant abnormalities, aside from chronic HBV infection in medical history (e.g., moderate severe liver disease other than chronic HBV, acute coronary syndrome within 6 months of screening, major surgery within 3 months of screening, significant/unstable cardiac disease, uncontrolled diabetes, bleeding diathesis or coagulopathy) or physical examination.
• Co-infection with:
• a) Current history of Hepatitis C infection or participants that have been cured for \<12 months at the time of screening b) Human immunodeficiency virus (HIV), c) Hepatitis D virus.
• History of or suspected liver cirrhosis and/or evidence of cirrhosis.
• Diagnosed or suspected hepatocellular carcinoma.
• History of malignancy within the past 5 years except for specific cancers that are cured by surgical resection (e.g., skin cancer). Participants under evaluation for possible malignancy are not eligible.
• History of vasculitis or presence of symptoms and signs of potential vasculitis (e.g., vasculitic rash, skin ulceration, repeated blood detected in urine without identified cause) current or history of an autoimmune condition or history/presence of other diseases that may be associated with vasculitis condition (e.g., systemic lupus erythematosus, rheumatoid arthritis, relapsing polychondritis, mononeuritis multiplex).
• History of extrahepatic disorders possibly related to HBV immune conditions (e.g., nephrotic syndrome, any type of glomerulonephritis, polyarteritis nodosa, cryoglobulinemia, uncontrolled hypertension).
• History of alcohol or drug abuse/dependence.
• Currently taking, or took within 3 months of screening, any immunosuppressing drugs (e.g., prednisone), other than a short course of therapy (≤2 weeks) or topical/inhaled steroid use.
• Participants to whom immunosuppressive treatment, including therapeutic doses of steroids is contraindicated, should not be considered for enrolment in the study.
• Currently taking, or has taken within 12 months of Screening, any interferon containing therapy.
• Participants requiring anti coagulation therapies (e.g., warfarin, Factor Xa inhibitors) or anti-platelet agents (like clopidogrel or aspirin) unless treatment can safely be discontinued throughout duration of the study, by the discretion of the investigator. Occasional use is permitted.
• Prior treatment with any oligonucleotide or siRNA within 12 months prior to the first dosing day.
• Prior treatment with bepirovirsen.

Sponsors & Collaborators

• GlaxoSmithKline: lead

Study Sites (177)

GSK Investigational Site

Chandler, Arizona, 85224, United States

Location

GSK Investigational Site

Davis, California, 95817, United States

Location

GSK Investigational Site

Los Angeles, California, 90027, United States

Location

GSK Investigational Site

Palo Alto, California, 94304, United States

Location

GSK Investigational Site

San Jose, California, 95128, United States

Location

GSK Investigational Site

Littleton, Colorado, 80120, United States

Location

GSK Investigational Site

Miami, Florida, 33134, United States

Location

GSK Investigational Site

Iowa City, Iowa, 52242, United States

Location

GSK Investigational Site

Baltimore, Maryland, 21287, United States

Location

GSK Investigational Site

Detroit, Michigan, 48377, United States

Location

GSK Investigational Site

Richmond, Virginia, 23219, United States

Location

GSK Investigational Site

Richmond, Virginia, 23249, United States

Location

GSK Investigational Site

Buenos Aires, 1061, Argentina

Location

GSK Investigational Site

Buenos Aires, C1061AAS, Argentina

Location

GSK Investigational Site

Buenos Aires, C1125ABE, Argentina

Location

GSK Investigational Site

Capital Federal, C1181ACI, Argentina

Location

GSK Investigational Site

Pilar, B1629AHJ, Argentina

Location

GSK Investigational Site

Rosario, S2002KDT, Argentina

Location

GSK Investigational Site

Aracaju, 49060-010, Brazil

Location

GSK Investigational Site

Campinas, 13034-685, Brazil

Location

GSK Investigational Site

Curitiba, 80810-050, Brazil

Location

GSK Investigational Site

Manaus, 69040-000, Brazil

Location

GSK Investigational Site

Porto Alegre, 90035003, Brazil

Location

GSK Investigational Site

Santa Maria, 97105-900, Brazil

Location

GSK Investigational Site

São Paulo, 05403-000, Brazil

Location

GSK Investigational Site

São Paulo, 08270-070, Brazil

Location

GSK Investigational Site

Vila Mariana, 04121-000, Brazil

Location

GSK Investigational Site

Sofia, 1431, Bulgaria

Location

GSK Investigational Site

Sofia, 1606, Bulgaria

Location

GSK Investigational Site

Sofia, Bulgaria

Location

GSK Investigational Site

Veliko Tarnovo, 5000, Bulgaria

Location

GSK Investigational Site

Vancouver, British Columbia, V6Z 2K5, Canada

Location

GSK Investigational Site

Victoria, British Columbia, V8V 3M9, Canada

Location

GSK Investigational Site

Ottawa, Ontario, K1H 8L6, Canada

Location

GSK Investigational Site

Toronto, Ontario, M5G 2C4, Canada

Location

GSK Investigational Site

Montreal, Quebec, H2X 0A9, Canada

Location

GSK Investigational Site

Montreal, Quebec, H4A 3J1, Canada

Location

GSK Investigational Site

Québec, Quebec, G1V 4G2, Canada

Location

GSK Investigational Site

Saint-Jérôme, Quebec, J7Z 2V4, Canada

Location

GSK Investigational Site

Beijing, 100015, China

Location

GSK Investigational Site

Beijing, 100050, China

Location

GSK Investigational Site

Beijing, China

Location

GSK Investigational Site

Changchun, 130021, China

Location

GSK Investigational Site

Chengdu, China

Location

GSK Investigational Site

Chongqing, 400042, China

Location

GSK Investigational Site

Fuzhou, 350025, China

Location

GSK Investigational Site

Guangzhou, 510060, China

Location

GSK Investigational Site

Guangzhou, 510515, China

Location

GSK Investigational Site

Guangzhou, 510630, China

Location

GSK Investigational Site

Hangzhou, 310000, China

Location

GSK Investigational Site

Hangzhou, 310003, China

Location

GSK Investigational Site

Kunming, 650021, China

Location

GSK Investigational Site

Nanjing, 210008, China

Location

GSK Investigational Site

Shanghai, 200025, China

Location

GSK Investigational Site

Shanghai, 200040, China

Location

GSK Investigational Site

Shanghai, 201506, China

Location

GSK Investigational Site

Shenyang, 110022, China

Location

GSK Investigational Site

Shenzhen, 518023, China

Location

GSK Investigational Site

Ürümqi, 830054, China

Location

GSK Investigational Site

Wuhan, 430022, China

Location

GSK Investigational Site

Xi'an, 710061, China

Location

GSK Investigational Site

Zhengzhou, 450000, China

Location

GSK Investigational Site

Zhenjiang, China

Location

GSK Investigational Site

Clermont-Ferrand, 63003, France

Location

GSK Investigational Site

Clichy, 92118, France

Location

GSK Investigational Site

Dijon, 21079, France

Location

GSK Investigational Site

Lille, 59037, France

Location

GSK Investigational Site

Pessac, 33604, France

Location

GSK Investigational Site

Poitiers, 86021, France

Location

GSK Investigational Site

Rennes, 35033, France

Location

GSK Investigational Site

Strasbourg, 67091, France

Location

GSK Investigational Site

Toulouse, 31059, France

Location

GSK Investigational Site

Berlin, 10243, Germany

Location

GSK Investigational Site

Berlin, 10439, Germany

Location

GSK Investigational Site

Berlin, 10787, Germany

Location

GSK Investigational Site

Berlin, 12163, Germany

Location

GSK Investigational Site

Bochum, 44787, Germany

Location

GSK Investigational Site

Cologne, 50668, Germany

Location

GSK Investigational Site

Düsseldorf, 40225, Germany

Location

GSK Investigational Site

München, 80336, Germany

Location

GSK Investigational Site

Athens, 10676, Greece

Location

GSK Investigational Site

Athens, 11527, Greece

Location

GSK Investigational Site

Periohi Dragana Alexand, 68100, Greece

Location

GSK Investigational Site

Rio Patras, 26504, Greece

Location

GSK Investigational Site

Kowloon, Hong Kong

Location

GSK Investigational Site

Pokfulam, Hong Kong

Location

GSK Investigational Site

Shatin, Hong Kong

Location

GSK Investigational Site

Budapest, 1097, Hungary

Location

GSK Investigational Site

Eger, 3300, Hungary

Location

GSK Investigational Site

Gyula, 5700, Hungary

Location

GSK Investigational Site

Miskolc, 3530, Hungary

Location

GSK Investigational Site

Belagavi, 590010, India

Location

GSK Investigational Site

Chandigarh, 160012, India

Location

GSK Investigational Site

Chennai, 600113, India

Location

GSK Investigational Site

Coimbatore, 641005, India

Location

GSK Investigational Site

Guhawati, 781006, India

Location

GSK Investigational Site

Hyderabad, 500033, India

Location

GSK Investigational Site

HyderabadTelangana, 500048, India

Location

GSK Investigational Site

Jaipur, 302001, India

Location

GSK Investigational Site

Ludhiana, 141001, India

Location

GSK Investigational Site

Manipal, 576104, India

Location

GSK Investigational Site

Mumbai, 400 008, India

Location

GSK Investigational Site

Mumbai, 400012, India

Location

GSK Investigational Site

Mumbai, 400026, India

Location

GSK Investigational Site

Pune, 411001, India

Location

GSK Investigational Site

Surat, 395002, India

Location

GSK Investigational Site

Brescia, 25123, Italy

Location

GSK Investigational Site

Foggia, 71100, Italy

Location

GSK Investigational Site

Messina, 98124, Italy

Location

GSK Investigational Site

Milan, 20122, Italy

Location

GSK Investigational Site

Milan, 20162, Italy

Location

GSK Investigational Site

Modena, 40126, Italy

Location

GSK Investigational Site

Chiba, 272-8516, Japan

Location

GSK Investigational Site

Ehime, 790-8524, Japan

Location

GSK Investigational Site

Fukuoka, 820-8505, Japan

Location

GSK Investigational Site

Fukuoka, 839-0863, Japan

Location

GSK Investigational Site

Gifu, 500-8717, Japan

Location

GSK Investigational Site

Gifu, 503-8502, Japan

Location

GSK Investigational Site

Hiroshima, 734-8551, Japan

Location

GSK Investigational Site

Hiroshima, 737-0023, Japan

Location

GSK Investigational Site

Hokkaido, 053-8506, Japan

Location

GSK Investigational Site

Hyōgo, 660-8550, Japan

Location

GSK Investigational Site

Kumamoto, 862-8655, Japan

Location

GSK Investigational Site

Miyagi, 980-8574, Japan

Location

GSK Investigational Site

Tokyo, 113-8519, Japan

Location

GSK Investigational Site

Tokyo, 173-8610, Japan

Location

GSK Investigational Site

Tokyo, 180-8610, Japan

Location

GSK Investigational Site

George Town, Malaysia

Location

GSK Investigational Site

Johor Bahru, 80100, Malaysia

Location

GSK Investigational Site

Kota Bharu Kelantan, Malaysia

Location

GSK Investigational Site

Kota Kinabalu, Malaysia

Location

GSK Investigational Site

Kuala Lumpur, Malaysia

Location

GSK Investigational Site

Kuantan, Malaysia

Location

GSK Investigational Site

Guadalajara, 44160, Mexico

Location

GSK Investigational Site

Oaxaca City, 68000, Mexico

Location

GSK Investigational Site

Panama City, 07206, Panama

Location

GSK Investigational Site

Bytom, 41-902, Poland

Location

GSK Investigational Site

Krakow, 31-202, Poland

Location

GSK Investigational Site

Łańcut, 37-100, Poland

Location

GSK Investigational Site

Bucharest, 021105, Romania

Location

GSK Investigational Site

Bucharest, 20125, Romania

Location

GSK Investigational Site

Cluj-Napoca, 400162, Romania

Location

GSK Investigational Site

Iași, 700116, Romania

Location

GSK Investigational Site

Suceava, 720224, Romania

Location

GSK Investigational Site

Timișoara, 300001, Romania

Location

GSK Investigational Site

Singapore, 119074, Singapore

Location

GSK Investigational Site

Singapore, 169608, Singapore

Location

GSK Investigational Site

Ansan, 15355, South Korea

Location

GSK Investigational Site

Busan, 47392, South Korea

Location

GSK Investigational Site

Daegu, 42601, South Korea

Location

GSK Investigational Site

Daegu, 700-721, South Korea

Location

GSK Investigational Site

Seoul, 03080, South Korea

Location

GSK Investigational Site

Seoul, 06351, South Korea

Location

GSK Investigational Site

Seoul, 07061, South Korea

Location

GSK Investigational Site

Seoul, 08308, South Korea

Location

GSK Investigational Site

Barcelona, 08035, Spain

Location

GSK Investigational Site

Barcelona, 08036, Spain

Location

GSK Investigational Site

León, 24080, Spain

Location

GSK Investigational Site

Madrid, 28041, Spain

Location

GSK Investigational Site

Málaga, 29010, Spain

Location

GSK Investigational Site

Salamanca, 37007, Spain

Location

GSK Investigational Site

Santander, 39008, Spain

Location

GSK Investigational Site

Valencia, 46014, Spain

Location

GSK Investigational Site

Valladolid, 47003, Spain

Location

GSK Investigational Site

Vigo, 36002, Spain

Location

GSK Investigational Site

Kaohsiung City, 807, Taiwan

Location

GSK Investigational Site

Kaohsiung City, 833, Taiwan

Location

GSK Investigational Site

Taichung, 40705, Taiwan

Location

GSK Investigational Site

Taipei, 104, Taiwan

Location

GSK Investigational Site

Tau-Yuan, 333, Taiwan

Location

GSK Investigational Site

Bangkok, 10330, Thailand

Location

GSK Investigational Site

Ankara, 06230, Turkey (Türkiye)

Location

GSK Investigational Site

Birmingham, B15 2TH, United Kingdom

Location

GSK Investigational Site

Edinburgh, EH4 2XU, United Kingdom

Location

GSK Investigational Site

Leeds West Yorkshire, LS9 7TF, United Kingdom

Location

GSK Investigational Site

London, SE5 9RS, United Kingdom

Location

GSK Investigational Site

London, SW17 0QT, United Kingdom

Location

MeSH Terms

Conditions

Hepatitis B, Chronic; Hepatitis; Hepatitis, Chronic; Hepatitis B

Condition Hierarchy (Ancestors)

Blood-Borne Infections; Communicable Diseases; Infections; Hepadnaviridae Infections; DNA Virus Infections; Virus Diseases; Hepatitis, Viral, Human; Liver Diseases; Digestive System Diseases; Chronic Disease; Disease Attributes; Pathologic Processes; Pathological Conditions, Signs and Symptoms

Study Officials

• GSK Clinical Trials

  GlaxoSmithKline

  STUDY DIRECTOR

Study Design

• Study Type: interventional
• Phase: phase 3
• Allocation: RANDOMIZED
• Masking: QUADRUPLE
• Who Masked: PARTICIPANT, CARE PROVIDER, INVESTIGATOR, OUTCOMES ASSESSOR
• Masking Details: This will be a double blinded study in which investigators/site staff and the Sponsor will remain blinded to treatment assignment.
• Purpose: TREATMENT
• Intervention Model: PARALLEL
• Sponsor Type: INDUSTRY
• Responsible Party: SPONSOR

Model Details: This is a multicenter, randomized, double-blind, placebo-controlled study.

Study Record Dates

• First Submitted: November 21, 2022
• First Posted: November 30, 2022
• Study Start: December 7, 2022
• Primary Completion: November 11, 2025
• Study Completion: May 5, 2026
• Last Updated: December 15, 2025

Record last verified: 2025-12

Data Sharing

• IPD Sharing: Will share
• Shared Documents: STUDY PROTOCOL, SAP, ICF, CSR
• Time Frame: Anonymized IPD will be made available within 6 months of publication of primary, key secondary and safety results for studies in product with approved indication(s) or terminated asset(s) across all indications.
• Access Criteria: Anonymized IPD is shared with researchers whose proposals are approved by an Independent Review Panel and after a Data Sharing Agreement is in place. Access is provided for an initial period of 12 months but an extension may be granted, when justified, for up to 6 months.

Locations

ME (2); TW (5); AR (6); MY (6); GR (4); JP (15); FR (9); DE (8); ES (10); KR (8); TU (1); IT (6); GB (5); SG (2); TH (1); BR (9); BU (4); CN (24); HK (3); US (12); PL (3); CA (8); IN (15); HU (4); RO (6); PA (1)